Literature DB >> 9918857

p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells.

S Zhang1, H E Broxmeyer.   

Abstract

Flt3/Flk2 belongs to class III receptor tyrosine kinases. Like other members of type III receptor tyrosine kinases, murine Flt3 induces tyrosine phosphorylation of p85 and subsequently activation of PI3 kinase upon FL binding. While p85 binds murine Flt3 at Y958 in the carboxyl terminus of the receptor, human Flt3 does not have a potential p85-binding site in the carboxyl terminus. In this study, we examined whether p85 binds to human Flt3 in Baf3/Flt3 and THP-1 cells. In contrast to murine Flt3, p85 is not tyrosine phosphorylated after FL stimulation, nor does it bind Flt3 in both cell lines. Instead p85 associates inducibly with tyrosine phosphorylated SHP-2 and constitutively with SHIP and two tyrosine phosphorylated proteins with molecular weights about 100-kDa (p100) and 120-kDa (p120) in Baf3/Flt3 cells. The p100 associates with both p85 and SHP-2. In THP-1 cells, p85 associates inducibly with tyrosine phosphorylated SHIP, p100 and p120. These results indicate that p85 does not bind human Flt3, but forms a complex with SHP-2, SHIP, p100 and p120 in hematopoietic cells. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918857     DOI: 10.1006/bbrc.1998.9959

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.

Authors:  Raghuveer Singh Mali; Peilin Ma; Li-Fan Zeng; Holly Martin; Baskar Ramdas; Yantao He; Emily Sims; Sarah Nabinger; Joydeep Ghosh; Namit Sharma; Veerendra Munugalavadla; Anindya Chatterjee; Shuo Li; George Sandusky; Andrew W Craig; Kevin D Bunting; Gen-Sheng Feng; Rebecca J Chan; Zhong-Yin Zhang; Reuben Kapur
Journal:  Blood       Date:  2012-07-17       Impact factor: 22.113

2.  Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.

Authors:  Obdulio Piloto; Melissa Wright; Patrick Brown; Kyu-Tae Kim; Mark Levis; Donald Small
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

Review 3.  Signal transduction of oncogenic Flt3.

Authors:  Chunaram Choudhary; Carsten Müller-Tidow; Wolfgang E Berdel; Hubert Serve
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

Review 4.  Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model.

Authors:  Perry M Chan
Journal:  Protein Cell       Date:  2011-02-25       Impact factor: 14.870

Review 5.  Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.

Authors:  Yun Chen; Yihang Pan; Yao Guo; Wanke Zhao; Wanting Tina Ho; Jianlong Wang; Mingjiang Xu; Feng-Chun Yang; Zhizhuang Joe Zhao
Journal:  Stem Cell Investig       Date:  2017-06-02

6.  Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.

Authors:  Elly V Barry; Jennifer J Clark; Jan Cools; Johannes Roesel; D Gary Gilliland
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

Review 7.  A role for SHIP in stem cell biology and transplantation.

Authors:  William G Kerr
Journal:  Curr Stem Cell Res Ther       Date:  2008-05       Impact factor: 3.828

8.  Survey of activated FLT3 signaling in leukemia.

Authors:  Ting-lei Gu; Julie Nardone; Yi Wang; Marc Loriaux; Judit Villén; Sean Beausoleil; Meghan Tucker; Jon Kornhauser; Jianmin Ren; Joan MacNeill; Steven P Gygi; Brian J Druker; Michael C Heinrich; John Rush; Roberto D Polakiewicz
Journal:  PLoS One       Date:  2011-04-28       Impact factor: 3.240

9.  BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML.

Authors:  W-H Lin; W-T Jiaang; C-W Chen; K-J Yen; S-Y Hsieh; S-C Yen; C-P Chen; K-Y Chang; C-Y Chang; T-Y Chang; Y-L Huang; T-K Yeh; Y-S Chao; C-T Chen; J T-A Hsu
Journal:  Br J Cancer       Date:  2011-12-20       Impact factor: 7.640

10.  Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling.

Authors:  S Zhang; S Fukuda; Y Lee; G Hangoc; S Cooper; R Spolski; W J Leonard; H E Broxmeyer
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.